Spain Brugada Syndrome Market Analysis

Spain Brugada Syndrome Market Analysis


$ 3999

The Spain Brugada Syndrome Market was valued at $23.2 Mn in 2023 and is predicted to grow at a CAGR of 6.8% from 2023 to 2030, to $36.7 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. The prominent players of the Spain Brugada Syndrome Market are Bayer, Roche, Siemens Healthineers, Sanofi, Thermo Fisher Scientific, and Novartis, among others.

ID: IN10ESPH573 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Aarti Patel

Buy Now

Spain Brugada Syndrome Market Executive Summary

The Spain Brugada Syndrome Market is at around $23.2 Mn in 2023 and is projected to reach $36.7 Mn in 2030, exhibiting a CAGR of 6.8% during the forecast period.

Brugada syndrome is a rare, but potentially threatening, genetic condition that causes abnormal electrical activity in the heart, leading to an increased risk of sudden cardiac death. People with Brugada syndrome have an increased risk of irregular heart rhythms beginning in the lower chambers of the heart, i.e., the ventricles. Common signs and symptoms associated with Brugada Syndrome include dizziness, fainting, gasping and laboured breathing, particularly at night, irregular heartbeats or palpitations, extremely fast and chaotic heartbeat, and seizures. The risk factors for Brugada syndrome include family history of Brugada syndrome, being male, race, and fever.

Cardiovascular diseases are the leading cause of death in Spain accounting for more than 30% deaths, according to data from the National Institute of Statistics, with the lack of control of cardiovascular risk factors (CVRF) being the main contributing factor. The Spain Brugada Syndrome Market is driven by significant factors such as growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. However, high cost of treatment, side effects and complications of treatment, and limited R&D restrict the growth and potential of the market.

The major players of the Spain Brugada Syndrome Market are Bayer, Roche, Siemens Healthineers, Sanofi, Thermo Fisher Scientific, and Novartis, among others.

Spain Brugada Syndrome Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Growing Prevalence of Cardiovascular Diseases: In Spain, cardiovascular disease stands as the leading cause of death, responsible for 32% of all fatalities. This increase in cardiovascular diseases is significantly enhancing the Brugada syndrome market by intensifying the focus on cardiovascular health and genetic disorders. With the growing prevalence of heart-related issues, there is a greater emphasis on and investment in diagnostic and treatment solutions for conditions like Brugada syndrome. This surge in awareness and the demand for specialized care are propelling market growth, resulting in advancements in the detection, management, and treatment of Brugada syndrome in the country.

Increasing Awareness and Diagnosis: In Spain, the growing awareness of Brugada syndrome is a key driver of market expansion. As healthcare professionals and the public become more informed about the condition, diagnoses are made more frequently and at earlier stages, leading to timely interventions. This surge in awareness fuels the demand for sophisticated diagnostic equipment and treatment methods, resulting in increased investments and advancements within the market. Improved educational and awareness campaigns contribute to a more knowledgeable patient population and encourage proactive management of Brugada syndrome, thereby further propelling market growth in Spain.

Advancements in Genetic Testing: In Spain, the Brugada syndrome market is significantly bolstered by advancements in genetic testing. These advancements enhance the accuracy and speed of identifying individuals at risk. Cutting-edge genetic testing technologies facilitate precise diagnoses, enabling early interventions and personalized treatment plans. This improved diagnostic ability raises patient awareness and drives demand for targeted therapies, leading to market growth and encouraging innovation in the management of Brugada syndrome.

Market Restraints

High Cost of Treatment: The treatment of Brugada syndrome is often expensive, primarily due to the need for implantable cardioverter-defibrillators (ICDs) and ongoing medication. These high costs can be a significant obstacle for many patients, making it difficult for them to access necessary care and, consequently, limiting the growth of the Brugada syndrome market.

Side Effects and Complications of Treatments: The severe and potentially fatal complications associated with Brugada syndrome, such as sudden cardiac arrest occurring during sleep, pose a major challenge for the market. The fear of these life-threatening events may deter individuals from pursuing diagnosis and treatment. This also hampers the development of preventive measures, as the limited number of patients available for clinical trials restricts research efforts.

Limited R&D: The Brugada syndrome market faces significant growth challenges due to a lack of investment in research and development. As a rare disease, it often receives less research attention compared to more common conditions. This lack of focus hinders the development of advanced diagnostic tools, treatments, and preventive strategies, thereby restricting market growth by limiting the availability of effective treatments and delaying their entry into the market. This creates uncertainties for patients and healthcare providers regarding disease management and prognosis.

Regulatory Landscape and Reimbursement Scenario

The regulatory body for pharmaceuticals in Spain is the Spanish Agency of Medicines and Medical Devices (AEMPS, Agencia Española de Medicamentos y Productos Sanitarios) which operates under the Ministry of Health, Social Services, and Equality. AEMPS plays a critical role in safeguarding the public health in Spain by ensuring the efficacy, safety, and quality of pharmaceuticals, including both human and veterinary medications. For novel medications meant for the Spanish market, AEMPS evaluates applications and issues marketing authorizations. They also oversee the lifecycle of drugs that have previously received approval.

The pharmaceutical companies must submit a completed MAA (Marketing Authorization Application) which can be used for drugs meant for the Spain market (National Procedure) or for the drugs intended for commercialization throughout the European Union (EU) through the EMA (European Medicines Agency). Through the EMA, products can be authorized through the National Procedure, the Centralised Procedure (CP), Decentralised Procedure (DCP) or Mutual Recognition Procedure (MRP). In this case, AEMPS acts as a national competent authority (NCA) within the EMA framework. It then issues a final decision of either approval, conditional approval or refusal after conducting a review and evaluation of the MAA based on safety, efficacy, quality, and risk-benefit ratio. Even after entering the market, AEMPS and other stakeholders continue to monitor the drug’s safety profile through pharmacovigilance by gathering and examining adverse reaction data.

In Spain, the Ministry of Health (MOH) is the department of the central government responsible for approving reimbursement of medicinal products. When AEMPS grants final authorization for the packaging materials to be used in Spain, the process of pricing and reimbursement for a centrally approved pharmaceutical product starts. After AEMPS has given its approval for the product’s final packaging, it will document this decision and notify the MAH as well as the General Directorate for Pharmacy and Medical Devices, which is the body within the MOH competent to decide on reimbursement. The central government is the primary decision-maker in the reimbursement process. The MOH determines price and reimbursement after consulting with the ICPM and the General Directorate for Pharmacy and Medical Devices. The maximum amount that can be paid is determined by the ICPM after the General Directorate for Pharmacy and Medical Devices makes the initial decision about the product's reimbursement status.

Competitive Landscape

Key Players

Here are some of the major key players in the Spain Brugada Syndrome Market:

  • Bayer
  • Roche
  • Siemens Healthineers
  • Sanofi
  • Thermo Fisher Scientific
  • Novartis
  • Boehringer Ingelheim
  • Merck
  • Johnson & Johnson
  • B. Braun

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Spain Brugada Syndrome Market Segmentation

By Diagnosis

  • Electrocardiogram
  • Electrophysiology (Ep) Test
  • Genetic Testing

By Treatment

  • Implantable Cardioverter-Defibrillator
  • Drug Therapy

By End User

  • Hospitals
  • Clinics
  • Diagnostic Centres

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 09 September 2024
Updated by: Bhanu Pratap Singh

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up